Federal grand jury to examine Vioxx marketing
Pharma Compliance Alert, February 6, 2008
A federal grand jury is investigating whether Merck promoted its painkiller Vioxx for off-label uses, according to an article in The Wall Street Journal.
Merck pulled Vioxx from the market in 2004 after a study linked it to an increased risk of heart attacks and strokes. The company tentatively agreed to a $4.85 billion settlement for lawsuits filed by people who claimed they were injured by Vioxx.
In a regulatory filing, Merck stated the Department of Justice subpoenaed information relating to the company's research, marketing, and sales of Vioxx. In addition 31 state attorneys general and the District of Columbia are investigating the sales and marketing of Vioxx.
Comments
0 comments on “Federal grand jury to examine Vioxx marketing ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- What does case-mix index mean to you?
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Searched